Opendata, web and dolomites


From symptom relief to disease modifying allergy treatment with Glycan-Allergen Immunotherapy

Total Cost €


EC-Contrib. €






 GAIT project word cloud

Explore the words cloud of the GAIT project. It provides you a very rough idea of what is the project "GAIT" about.

therapeutics    chronic    pharmaceutical    diseases    trials    allergen    iia    allergens    therapy    annual    plans    treat    mechanisms    recognition    elaborated    antihistamines    business    pace    shown    disease    negotiations    20    relieving    healthy    alleviating    strategy    worldwide    followed    responsible    investors    decongestants    generation    doses    individuals    global    severe    allergy    sia    grass    immune    alarming    market    refine    protein    vivo    sme    license    dose    curative    plan    treatment    initialize    placebo    medical    ait    symptom    extract    ipr    cured    licensing    characterised    underlying    proprietary    modifying    elaborate    instead    protection    attempts    suited    profitability    glycans    medicine    inducing    immunotherapy    incorporated    prevalence    harm    dc4u    tolerance    patient    substances    healthcare    pollen    dominated    gp    corticosteroids    endogenous    course    self    risks    replace    human    company    develops    safe    life    efficacy    clinical   

Project "GAIT" data sheet

The following table provides information about the project.


Organization address
address: DE CORRIDOR 21E
postcode: 3621 ZA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DC4U NL (BREUKELEN) coordinator 50˙000.00


 Project objective

The annual increase in prevalence of allergy related diseases develops at an alarming pace worldwide. Responsible disease mechanisms are characterised by unwanted immune responses to substances which do not harm healthy individuals. The allergy therapeutics market is now dominated by symptom alleviating antihistamines, decongestants and corticosteroids. The main patient need is to get cured with a disease modifying medicine instead of the chronic use of symptom relieving products. Allergen-specific Immunotherapy (AIT) attempts to treat the underlying cause by inducing allergen-specific immune tolerance. However, currently used AIT with high doses of extract is not effective enough (only 20% better than placebo), risks severe side effects and requires 5 years of treatment.

DC4U is developing a new generation of disease modifying allergy treatment with the potential to replace symptom relieving products and current AIT. We apply a new and unique technology to present allergens to the immune system as being SELF and SAFE, using glycans as endogenous human protein recognition elements. Our lead product, “sia-GP”, is a grass pollen allergy treatment for life long protection, achieved in a short treatment course. DC4U has shown highly promising in-vivo dose-response efficacy results and will further develop this proprietary product up to and including Phase IIa clinical trials. This will be followed by out-licensing to a pharmaceutical company. Effective curative tolerance inducing therapy will contribute to global medical needs and reduction of healthcare costs.

In this SME-1 we will elaborate and refine our clinical plans, IPR strategy, market analysis and profitability analysis. Furthermore, we will initialize discussions and negotiations with several possible investors and licensing partners. All will be incorporated in an elaborated European business plan with best suited to out-license sia-GP after Phase IIa clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GAIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GAIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More